Cardarine/GW50156 Bloodwork results

[Dado5]

I have been using GW-501515 at 10mg/day and it makes me really tired and i cant finish my workout. Not sure why...

 

[johnjuanb1]

I have been using GW-501515 at 10mg/day and it makes me really tired and i cant finish my workout. Not sure why...

Are you on low carbs? Doesn’t GW use fat for energy?
Mike Arnold would know the chemistry behind it. Maybe he can recommend a way to make it work for you. GW makes me feel great but i eat 2 cups of rice with my meals.

 

[Mike Arnold]

So how about this in a bulk cycle which contains orals that cause lipid issues.

That is a perfect application for GW. As we all know, methylated AAS wreak havoc on cholesterol levels, so taking GW at this time--more than any other--makes sense.

 

[Dado5]

I take good amount of carbs thru the day plus 40g carb drink before workout.
But i also can take Clen or Ephedra with 500mg of caffeine right before going to bed and sleep like a baby.
Some stuff affects me in a weird way..

Are you on low carbs? Doesn’t GW use fat for energy?
Mike Arnold would know the chemistry behind it. Maybe he can recommend a way to make it work for you. GW makes me feel great but i eat 2 cups of rice with my meals.

 

[aphextwin]

I know this is an old post, but I didn’t know that just 10 mg improved your lipids. I just back using it at 20 mg….great for cardio. Love this stuff.

 

[Matsuo Munefusa]

I know this is an old post, but I didn’t know that just 10 mg improved your lipids. I just back using it at 20 mg….great for cardio. Love this stuff.

Yeah a few percent improvement. It’s not a miracle but it helps.

 

[juggy38]

I think it helps A1C also

What I would like to see is someone other than @nothuman with excellent HDL run it. Like after anavar. My HDL was like 9. NINE. After a 75mg day anavar run

 

[Matsuo Munefusa]

I think it helps A1C also

What I would like to see is someone other than @nothuman with excellent HDL run it. Like after anavar. My HDL was like 9. NINE. After a 75mg day anavar run

Not surprised. Orals destroy HDL and it doesn’t bounce back as good as it was before either always. Chalk that up to another thing I wish somebody had mentioned to me before it was too late.

 

[juggy38]

Not surprised. Orals destroy HDL and it doesn’t bounce back as good as it was before either always. Chalk that up to another thing I wish somebody had mentioned to me before it was too late.

I’m currently running test/DHB, and my HDL is never “great”. I’ll give it another 2-3 weeks, make sure my HDL is shit, and maybe see what 6 weeks 10mg does.

There is a bigger brother of GW out now, GW 0742.

 

[Mike Arnold]

Yeah a few percent improvement. It’s not a miracle but it helps.

It is very effective for a lot of people. See below....

Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome​

Eric J Olson 1, Gregory L Pearce, Nigel P Jones, Dennis L Sprecher
Affiliations expand

• PMID: 22814748
• DOI: 10.1161/ATVBAHA.112.247890

Abstract​

Objective: Peroxisome proliferator-activated receptor-δ-induced upregulation in skeletal muscle fatty acid oxidation would predict the modulation of lipid/lipoproteins.


Methods and results: GW501516 (2.5, 5.0, or 10.0 mg) or placebo was given for 12 weeks to patients (n=268) with high-density lipoprotein (HDL) cholesterol <1.16 mmol/L. Fasting lipids/apolipoproteins (apos), insulin, glucose, and free fatty acid were measured; changes from baseline were calculated and assessed. A second smaller exploratory study (n=37) in a similar population was conducted using a sequence of 5 and 10 mg dosing for the assessment of lipoprotein particle concentration. GW501516 demonstrated HDL cholesterol increases up to 16.9% (10 mg) and apoA-I increases up to 6.6%. Reductions were observed in low-density lipoprotein (LDL) cholesterol (-7.3%), triglycerides (-16.9%), apoB (-14.9%), and free fatty acids (-19.4%). The exploratory study showed significant reductions in the concentration of very LDL (-19%), intermediate-density lipoprotein (-52%), and LDL (-14%, predominantly a reduction in small particles), whereas the number of HDL particles increased (+10%; predominantly medium and large HDL).


Conclusions: GW501516 produced significant changes in HDL cholesterol, LDL cholesterol, apoA1, and apoB. Fewer very LDL and larger LDL support a transition toward less atherogenic lipoprotein profiles. These data are consistent with peroxisome proliferator-activated receptor-δ being a potentially important target for providing cardiovascular protection in metabolic syndrome-like patients.

 

[Matsuo Munefusa]

It is very effective for a lot of people. See below....

Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome​

Eric J Olson 1, Gregory L Pearce, Nigel P Jones, Dennis L Sprecher
Affiliations expand

• PMID: 22814748
• DOI: 10.1161/ATVBAHA.112.247890

Abstract​

Objective: Peroxisome proliferator-activated receptor-δ-induced upregulation in skeletal muscle fatty acid oxidation would predict the modulation of lipid/lipoproteins.


Methods and results: GW501516 (2.5, 5.0, or 10.0 mg) or placebo was given for 12 weeks to patients (n=268) with high-density lipoprotein (HDL) cholesterol <1.16 mmol/L. Fasting lipids/apolipoproteins (apos), insulin, glucose, and free fatty acid were measured; changes from baseline were calculated and assessed. A second smaller exploratory study (n=37) in a similar population was conducted using a sequence of 5 and 10 mg dosing for the assessment of lipoprotein particle concentration. GW501516 demonstrated HDL cholesterol increases up to 16.9% (10 mg) and apoA-I increases up to 6.6%. Reductions were observed in low-density lipoprotein (LDL) cholesterol (-7.3%), triglycerides (-16.9%), apoB (-14.9%), and free fatty acids (-19.4%). The exploratory study showed significant reductions in the concentration of very LDL (-19%), intermediate-density lipoprotein (-52%), and LDL (-14%, predominantly a reduction in small particles), whereas the number of HDL particles increased (+10%; predominantly medium and large HDL).


Conclusions: GW501516 produced significant changes in HDL cholesterol, LDL cholesterol, apoA1, and apoB. Fewer very LDL and larger LDL support a transition toward less atherogenic lipoprotein profiles. These data are consistent with peroxisome proliferator-activated receptor-δ being a potentially important target for providing cardiovascular protection in metabolic syndrome-like patients.

Like I said a few percent. If you have an HDL of 35 you might get to 40 but probably more likely stabilize around 38 or so after being on awhile.

I think it’s a great supp but again it’s not gonna pull a miracle for you.

 

[Mike Arnold]

Like I said a few percent. If you have an HDL of 35 you might get to 40 but probably more likely stabilize around 38 or so after being on awhile.

I think it’s a great supp but again it’s not gonna pull a miracle for you.

"GW501516 demonstrated HDL cholesterol increases up to 16.9% (10 mg)"

16.9% is pretty darn significant...especially when someone has a very low starting HDL.

 

[Matsuo Munefusa]

"GW501516 demonstrated HDL cholesterol increases up to 16.9% (10 mg)"

16.9% is pretty darn significant...especially when someone has a very low starting HDL.

Agreed. That 16% would turn a 35 HDL into a 40 HDL and we’re entering a zone there I’m pretty comfortable with. Cardarine is the good shit.